News & Views
SSB signs distribution deal for endonuclease
May 22 2012
Sartorius Stedim Biotech (SSB) has signed a worldwide sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications. The customised endonuclease is available under the product name Denarase through all regular SSB sales channels.
c-LEcta has optimised the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins.
“This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance,”said Dr. Uwe Gottschalk, VicePresident of Purification Technologies at Sartorius Stedim Biotech.
“The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total
solution provider for the biopharmaceutical industry.”
Dr. Marc Struhalla, Managing Director of c-LEcta added: “The technology developed by
c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialisation of our product.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia